GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All conditions

GLP-1 Therapy and Hypertension in India — What to Know

Last reviewed 12 May 2026 · Indian guideline context

The short answer

GLP-1 therapy is not directly approved for hypertension in India, but trials consistently show 3-8 mmHg systolic BP reduction as a secondary effect of weight loss + cardiometabolic improvement. For hypertensive patients with obesity (BMI ≥27.5 or ≥25 with comorbidities), GLP-1 under the obesity indication can meaningfully improve BP control. SELECT trial showed strong cardiovascular protection. Take the 5-min eligibility check.

See if you’re a candidate

The 5-minute Indian-guideline eligibility check factors in your Hypertension status.

Take the free assessment →

Hypertension in India — the context

Hypertension affects an estimated 220 million Indian adults — roughly 1 in 3 adults over age 30 (NFHS-5, 2019-21). Among hypertensive Indians, only ~25% have BP controlled to target. Comorbid obesity is present in 30-50% of urban Indian hypertensive patients, creating a strong case for weight-loss-driven cardiometabolic intervention. Indian cardiology and endocrinology societies have begun recognizing GLP-1 as relevant in obesity-comorbid hypertension, particularly given SELECT trial outcomes.

How GLP-1 helps — mechanism + evidence

GLP-1 receptor agonists reduce blood pressure indirectly through weight loss, improved vascular endothelial function, reduced sodium retention, and improved insulin sensitivity. Typical BP reduction: ~3-8 mmHg systolic, 1-4 mmHg diastolic at standard doses, depending on baseline. The SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with obesity + established CVD (mostly hypertensive). GLP-1 does not replace antihypertensive medications but is a meaningful adjunct in obesity-comorbid hypertension.

Key trials

  • SELECT: Semaglutide 2.4 mg reduced MACE by 20% over 3+ years in obesity + CVD patients; BP reductions of 4-6 mmHg systolic contributed to outcomes.
  • STEP 1-5: Semaglutide 2.4 mg consistently lowered systolic BP by 5-7 mmHg as a secondary outcome in obesity trials.
  • SURMOUNT-1: Tirzepatide reduced systolic BP by 6-8 mmHg in obese participants alongside 15-22% weight reduction.
  • SUSTAIN-6: Semaglutide reduced MACE by 26% in T2D + CVD — BP reduction was a contributing factor.

Eligibility — who fits?

GLP-1 for hypertension in India is prescribed under the obesity indication (BMI ≥27.5 or ≥25 with comorbidities) or T2D indication, with hypertension as a comorbidity. The 5-min GLP-1 Check assessment factors in BMI, blood pressure, current antihypertensives, and CVD risk to map your fit. Patients with established cardiovascular disease who also have obesity have the strongest evidence base (SELECT) for GLP-1 benefit.

Indian-context considerations

  • •Existing antihypertensive medications often need dose review as weight drops — some patients can reduce or discontinue antihypertensives after 6-12 months of GLP-1 + sustained weight loss
  • •Salt sensitivity: Indian diet is typically high in sodium (pickles, papads, processed snacks) — pair GLP-1 with sodium reduction for best BP outcomes
  • •Indian stress + sleep patterns (long commutes, late dinners, low sleep) significantly drive hypertension — GLP-1 alone without lifestyle work yields limited BP benefit
  • •For patients with stage 2 hypertension (BP ≥160/100) or severe target organ damage, GLP-1 is an adjunct to — not a substitute for — proper antihypertensive therapy
  • •CVD-protection benefit (SELECT) is specific to semaglutide 2.4 mg in obesity + CVD — for hypertension without CVD, the benefit is primarily through weight loss

Brand options for Hypertension

Wegovy

Strongest evidence (SELECT) for cardiovascular protection in obesity + CVD (which usually includes hypertension). On-label for obesity at BMI ≥27.5 or ≥25 with comorbidity.

Mounjaro

Largest weight-loss outcomes (SURMOUNT). For severely obese hypertensive patients, the aggressive weight reduction often translates to meaningful BP improvements.

Ozempic

For hypertensive patients with T2D, Ozempic addresses both indications. SUSTAIN-6 evidence supports cardiovascular protection.

Full brand catalog: Semaglutide brands in India → · India pricing →

Patient pathway

Typical hypertension + obesity pathway: (1) take the 5-min GLP-1 Check assessment; (2) cardiology or internal medicine + endocrinology consult — ensure BP is reasonably controlled before starting GLP-1; (3) baseline labs (lipid profile, HbA1c, fasting glucose, creatinine, urine ACR for microalbuminuria); (4) start GLP-1 under the obesity indication; (5) reassess antihypertensive dosing at 3-6 months as weight drops — many patients can reduce medications; (6) ongoing BP monitoring (home BP or 24-hour ambulatory BP if needed).

Frequently asked questions

Will GLP-1 lower my blood pressure?+
Yes, modestly — typically 3-8 mmHg systolic reduction at standard doses, driven primarily by weight loss + cardiometabolic improvement. The effect is enhanced in patients who lose substantial weight (>10%). GLP-1 is not a substitute for antihypertensive medications; it is an adjunct.
Can I stop my BP medications if I take GLP-1?+
Not initially. Many patients on GLP-1 + sustained weight loss (>10%) are able to reduce or discontinue some antihypertensive medications after 6-12 months, under their physician's supervision. Never stop antihypertensive medications without medical guidance — abrupt discontinuation can cause dangerous BP rebound.
Is there a heart-attack-prevention benefit to GLP-1?+
Yes, for semaglutide and liraglutide. The SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MI, stroke, CV death) by 20% in obese patients with established cardiovascular disease. SUSTAIN-6 showed 26% MACE reduction in T2D + CVD. Tirzepatide CV outcomes trial (SURPASS-CVOT) results expected 2026-2027.
Will GLP-1 cause my heart rate to go up?+
GLP-1 RAs cause a small increase in resting heart rate (typically 2-5 bpm) as a class effect. This is generally well-tolerated and not clinically significant. Patients with pre-existing arrhythmias or significant tachyarrhythmia history should discuss with their cardiologist before starting.
How does GLP-1 affect cholesterol and lipids?+
GLP-1 RAs typically reduce LDL (~5-10%), reduce triglycerides (~10-20%), and may modestly raise HDL. Effects are largely driven by weight loss + insulin sensitivity. Patients with concurrent dyslipidaemia often continue statins; some reduce statin dose after sustained weight loss + lipid improvement.
Is GLP-1 safe for patients with existing heart disease?+
Generally yes — and in many cases, beneficial. The SELECT trial established cardiovascular benefit in obesity + established CVD with semaglutide 2.4 mg. Tirzepatide CV outcomes data are emerging. Patients with recent acute coronary events, severe heart failure (NYHA III-IV), or significant arrhythmias should discuss with cardiology before starting.
What lifestyle changes work best with GLP-1 for hypertension?+
Sodium reduction (target <5g salt/day), DASH-pattern eating, regular aerobic exercise (150 min/week), sleep optimization (7-8 hours), and stress management. The South Asian DASH adaptation (Indian DASH) modifies the standard plan for typical Indian dietary patterns — discuss with a nutritionist familiar with Indian cuisine.

Related conditions

Type 2 Diabetes

GLP-1 for Type 2 Diabetes — Indian context

Fatty Liver (NAFLD/MASLD)

GLP-1 for Fatty Liver (NAFLD/MASLD) — Indian context

Obstructive Sleep Apnea

GLP-1 for Obstructive Sleep Apnea — Indian context

See if GLP-1 fits your Hypertension profile

5 minutes. Uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Take the free assessment →

Educational content based on DCGI-approved labelling, peer-reviewed trials, RSSDI/ESI/INASL Indian clinical guidelines, and published literature. Not a substitute for a doctor’s clinical judgment. GLP-1 therapies are Schedule H drugs in India and require a doctor’s prescription. Always consult a qualified medical practitioner before starting any therapy.